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ABSTRACT
Basal-like breast cancers (BBCs) are enriched for increased EGFR expression and 
decreased expression of PTEN. We found that treatment with metformin and erlotinib 
synergistically induced apoptosis in a subset of BBC cell lines. The drug combination 
led to enhanced reduction of EGFR, AKT, S6 and 4EBP1 phosphorylation, as well as 
prevented colony formation and inhibited mammosphere outgrowth. Our data with 
other compounds suggested that biguanides combined with EGFR inhibitors have the 
potential to outperform other targeted drug combinations and could be employed 
in other breast cancer subtypes, as well as other tumor types, with activated EGFR 
and PI3K signaling. Analysis of BBC cell line alterations led to the hypothesis that 
loss of PTEN sensitized cells to the drug combination which was confirmed using 
isogenic cell line models with and without PTEN expression. Combined metformin and 
erlotinib led to partial regression of PTEN-null and EGFR-amplified xenografted MDA-
MB-468 BBC tumors with evidence of significant apoptosis, reduction of EGFR and AKT 
signaling, and lack of altered plasma insulin levels. Combined treatment also inhibited 
xenografted PTEN null HCC-70 BBC cells. Measurement of trough plasma drug levels 
in xenografted mice and a separately performed pharmacokinetics modeling study 
support possible clinical translation.
INTRODUCTION
Approximately 80% of breast cancers classified by 
gene expression as basal-like are identified clinically as 
triple negative [1]. Triple negative breast cancers (TNBCs) 
are defined by a lack of estrogen receptor expression and 
progesterone receptor expression, as well as an absence of 
human epidermal growth factor receptor 2 (ERBB2/HER2) 
amplification. BBCs are heterogeneous, but common 
molecular aberrations include overexpression of epidermal 
growth factor receptor (EGFR), loss of expression of 
phosphatase and tensin homolog deleted on chromosome 
ten (PTEN), as well as mutation of BRCA1, PIK3CA and 
p53 [2–5]. More recently, it has been shown that many 
BBCs harbor decreased expression of the PTPN12 tyrosine 
phosphatase and inositol polyphosphate 4-phosphatase 
type II (INPP4B), leading respectively to increased growth 
factor and PI3K pathway activation [6–8]. Overall, BBCs 
have the highest PI3K/AKT pathway activity among 
the different breast cancer subtypes [1]. While we await 
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clinical exploitation of these findings, BBCs retain a high 
rate of recurrence and death [9].
EGFR, due to its oncogenic properties and its 
overexpression in BBCs, provides an opportunity for 
targeted therapies [10]. Recently published data from the 
work of The Cancer Genome Atlas (TCGA) indicates that 
approximately 23% of BBCs harbor EGFR gene copy 
number gain [1]. Although EGFR expression correlates 
with poor prognosis, clinical trials incorporating EGFR 
inhibitors in TNBC have yielded only modest clinical 
results [11]. This may be due to the heterogeneous nature 
of BBCs in which not only the expression of EGFR is 
variable but also the activity of EGFR and dependence 
of the tumor on that activity. Furthermore, plausible 
explanations for primary resistance to single agent EGFR 
targeted therapy include continued activation of alternate 
receptors tyrosine kinases [e.g. c-Met and insulin-like 
growth factor 1 receptor (IGF1R)], signal feedback, or de-
coupling EGFR from downstream AKT signaling through 
loss of PTEN or INPP4B [7, 12–15]. Therefore, rational 
drug combinations with the goal of potentiating the effect 
of EGFR inhibitors in BBCs should be explored.
Metformin, a type 2 diabetes drug, has demonstrated 
antitumor effects in multiple cancer models [16–18]. 
Metformin has been shown to reduce EGFR, mitogen-
activated protein kinase (MAPK) and AKT signaling in 
breast cancer cell lines, and selectively induced apoptosis 
in TNBC cells [19, 20]. However, the clinical relevance 
of these in vitro findings remains uncertain due to the 
high doses of metformin required. Recently, metformin 
was shown to selectively kill tumor initiating cells at 
doses as low as 100 µM with corresponding potentiation 
of chemotherapy efficacy in xenograft models [21]. In 
addition, epidemiologic studies show that diabetic patients 
taking metformin have a lower mortality rate as well as 
a decreased risk of developing breast cancer [22, 23], 
although these results remain debatable due to possible 
methodology shortcomings [24, 25]. To clarify such 
ambiguity, continued research into the potential use of 
metformin as a cancer therapeutic is worthwhile.
The mechanisms of metformin’s anti-neoplastic 
properties are controversial. Metformin can reduce 
circulating glucose and insulin levels by inhibiting 
gluconeogenesis in the liver. This is accomplished 
through metformin’s ability to indirectly activate 
AMP-activated protein kinase (AMPK) by inhibiting 
oxidative phosphorylation in cells [26]. In cancer cells, 
this inhibition leads to reduced ATP production and 
cellular energy crisis[27]. Among its many substrates, 
activated AMPK inhibits mammalian target of rapamycin 
complex-1 (mTORC1) output and lipogenesis by 
phosphorylating tuberous sclerosis complex 2 (TSC2) and 
acetyl-CoA-carboxylase (ACC), respectively [28, 29]. In 
addition, metformin has recently been shown to directly 
inhibit mTORC1 activity in a RAG GTPase dependent 
manner and indirectly through the p53-REDD1 axis 
[30, 31]. Metformin has been shown to inhibit tumors in 
mice both by decreasing circulating growth factors and 
by directly inhibiting tumor cell growth and survival 
pathways. In one study, metformin delayed the outgrowth 
of tumors in PTEN heterozygous mice without altering the 
plasma insulin or IGF-1 levels [32]. In contrast, metformin 
prevented tumor formation in a toxin-mediated mouse 
model of lung cancer while reducing circulating IGF-1 and 
insulin levels, but without demonstrated ability to activate 
AMPK in lung tissue [18]. Although these data have not 
led to a unified mechanism of how metformin could inhibit 
or prevent human cancers, epidemiologic and preclinical 
evidence has inspired ongoing clinical trials.
Metformin’s ability to activate AMPK, as well as 
deactivate EGFR, AKT and mTORC1 provides a rationale 
for assessing whether metformin can synergize with EGFR 
inhibition to treat BBCs. In this study, we demonstrated 
that erlotinib (an EGFR kinase inhibitor) and metformin 
synergistically inhibited the growth and induced cell death 
in a subset of BBC cell lines with accompanying enhanced 
reduction of EGFR, AKT and mTORC1 signaling. We 
showed in an isogenic MCF10A cell model that loss 
of PTEN sensitized cells to the drug combination and 
conversely, introducing PTEN into PTEN-null tumor 
cell lines desensitized cells to the drug combination. 
This synergy was confirmed in vivo by demonstrating 
significant reduction in tumor burden after combined drug 
treatment as compared to treatment with either drug alone.
RESULTS
A subset of BBC lines is sensitive to combined 
treatment with metformin and erlotinib
To investigate the cell signaling status of various 
direct and indirect targets of erlotinib and metformin in 
BBCs, we examined the phosphorylation levels of EGFR, 
AMPK, AKT, S6 and 4E-binding protein 1 (4EBP1) in 
a panel of breast cancer cell lines. In general, there is 
increased phosphorylation of EGFR, AKT, S6 and 4EBP1 
in breast cancer cell lines compared with immortalized 
non-transformed human mammary epithelial cells 
(HMEC-hTERT), as well as a significant decrease in 
AMPK phosphorylation at Thr172 (Fig. 1A). Although 
the luminal breast cancer lines MCF7 and T47D expressed 
very low levels of total EGFR, they exhibited significant 
EGFR phosphorylation. The consistent activation of 
EGFR and the phosphoinositide 3-kinase (PI3K) pathway 
across various BBC lines, as well as a decrease in AMPK 
signal, provided a strong rationale for testing combined 
treatment with erlotinib and metformin.
To investigate whether combined metformin and 
erlotinib treatment is effective in BBCs, a panel of 17 breast 
cancer cell lines (16 BBC lines and one luminal line) was 
screened for synergy over a range of metformin (0.5 to 
4 mM) and erlotinib (2 to 4 µM) doses. We found that the 
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drug combination is synergistic in 8 of the lines (47.1%), 
additive in 4 (23.5%) and antagonistic in 5 others (29.4%) 
(Table 1). To test that the observed synergy was not due to 
off target effects of erlotinib, we repeated the experiment 
using BIBW-2992 (a dual EGFR/HER2 tyrosine kinase 
inhibitor) and metformin in HER2-negative MDA-MB-468 
cells and obtained similar results (Suppl. Table 1). These 
results demonstrate that inhibition of EGFR combined 
with the effects of metformin can synergistically inhibit 
the growth of a subset of BBC cell lines.
To probe what may contribute to the combined 
drug synergy, we assessed the expression of OCT1, 
OCT2, liver kinase beta 1 (LKB1) and PTEN in the BBC 
lines. The OCTs are cation transporters of metformin 
and their expression varies in different tissues [33–36]. 
We found that the majority of cell lines, including 
HMEC-hTERT, expressed significant amounts of both 
OCT1 and OCT2, indicating that differential sensitivity 
to the drug combination was not due to limitations in 
metformin transport (Fig. 1B). BT-549, with almost no 
expression of either OCT protein, is one of the lines 
in the “additive group” which is consistent with the 
existence of known additional metformin transporters 
(e.g. OCT3) [33]. In addition, analysis of RNA-seq 
results of the TCGA BBC data with z-score threshold of 
±1 using the cBio Cancer Genomics Portal [37] showed 
Figure 1: Dysregulation of signaling pathways and loss of PTEN expression in a panel of breast cancer cell lines. 
(A) Immunoblots of members of the EGFR, PI3K, mTOR, and AMPK signaling pathways in proliferating breast cancer cell lines 
(B) Immunoblots assessing the levels of PTEN, LKB1 and the cation transporters OCT1 and OCT2. PTEN mutant lines are marked with (*).
Table 1: Combination index of metformin and erlotinib treatment
Synergistic (CI) Additive (CI) Antagonistic (CI)
MDA-MB-468* (0.44) MX-1* (1.19) HCC-1187 (1.79)
MCF7 (0.46) HCC-1143 (0.97) HCC-38* (49.8)
MDA-MB-435S (0.27) BT-549* (1.00) MDA-MB-157 (2.04)
BT-20 (0.56) SUM-149* (0.82) MDA-MB-231 (15.4)




17 cell lines were treated with metformin and erlotinib as well as their combinations at various doses (6 replicates per 
treatment) and combination indices (CI) at metformin dose of 2 mM and erlotinib dose of 4 µM were determined using the 
software Compusyn. PTEN mutant lines are marked with (*)
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that a significant number of samples up-regulate gene 
expression of these OCT proteins, including OCT3 
[[1]; data not shown]. This suggests that metformin 
can effectively enter breast cancer cells. While we 
found reduced LKB1 expression (upstream of AMPK) 
in multiple cell lines, only SUM-149 cells completely 
lacked LKB1 expression. We also noted that all the 
lines with known PTEN mutations fall into either the 
synergistic or additive category with the exception of 
the HCC-38 cell line, which upon review of the Sanger 
database contains an interchromosomal breakpoint 
within PTEN (Table 1), and confirmed that all the PTEN 
mutant lines lack PTEN expression (Fig.  1B). Therefore 
PTEN mutation was noted as a possible determinant of 
sensitivity to combined treatment.
The combination of metformin and erlotinib 
inhibits EGFR, AKT, S6 and 4EBP1 signaling
MDA-MB-468 cells, highly sensitive to the drug 
combination, have known mutational abrogation of 
PTEN and p53, as well as amplification of EGFR. MDA-
MB-468 cells therefore serve as a good model for TNBC 
with highly active EGFR signaling. MDA-MB-468 cells 
showed dose-dependent response (reduction of EGFR 
signaling) to erlotinib ranging from 2.5 to 40 µM but doses 
required to significantly inhibit EGFR phosphorylation 
are higher than what is achievable in patients treated 
with approved doses and schedules (Fig. 2A). According 
to the erlotinib product information (Roche), the median 
minimum and maximum steady state plasma levels of 
Figure 2: Combined treatment with metformin and erlotinib synergistically reduces EGFR, AKT, S6 and 4EBP 
signaling. (A) Immunoblot of MDA-MB-468 cells treated for 24 hours with the indicated concentrations of erlotinib. (B) Immunoblots 
evaluating the dose-dependent signaling changes in EGFR, ACC, AMPK and S6 under metformin and AICAR treatments. (C) Immunoblots 
of signaling changes of EGFR, AKT, Erk1/2, S6 and 4EBP1 in MDA-MB-468 cells treated with metformin (2 mM), erlotinib (4 µM), 
rapamycin (10 nM) and AICAR (2 mM) and their combinations for 24 hours. (D) Immunoblots of signaling changes of AKT, S6 and 4EBP1 
in BT-20 cells treated with metformin (2 mM), erlotinib (4 µM) and their combination for 24 hours.
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erlotinib, in patients treated at a dose of 150 mg daily, 
are 2.7 µM and 4.6 µM respectively. The incomplete 
blockade of EGFR signaling by erlotinib in vitro at 
doses corresponding to median clinically achievable 
plasma levels highlights a need to identify a synergistic 
combination. We then investigated the effect of metformin 
on MDA-MB-468 cells and compared metformin’s effects 
with those of another AMPK agonist, 5-aminoimidazole-
4-carboxamide riboside (AICAR). As expected, there 
was a dose-dependent phosphorylation of AMPK and 
ACC, a downstream substrate of AMPK, when treated 
with metformin or AICAR (Fig. 2B). However, there 
was a strong dose-dependent inhibitory effect on the 
phosphorylation of S6 using metformin that was not 
observed when cells were treated with AICAR, indicating 
this inhibitory effect on S6 in MDA-MB-468 cells was 
AMPK independent (Fig. 2B).
To test whether metformin and erlotinib could 
cooperate in sustained inhibition of relevant signaling 
pathways, we analyzed cell signaling changes 24 hours 
after various drug treatments (metformin, erlotinib, 
AICAR and rapamycin) in MDA-MB-468 cells. We 
included AICAR and rapamycin since metformin has 
been shown to directly or indirectly act on their targets. 
We observed potentiation of erlotinib-induced inhibition 
of EGFR, ERK1/2 and AKT signaling with the addition 
of metformin which was not observed in the other tested 
drug combinations: erlotinib and rapamycin, erlotinib and 
AICAR, or metformin and rapamycin (Fig. 2C). Although 
rapamycin is effective at inhibiting the mTORC1 S6 
output, it is a poor inhibitor of 4EBP1 phosphorylation 
(Fig. 2C). Metformin, on the other hand, decreased 
phosphorylation of both S6 and 4EBP1 when used alone, 
and both outputs were further inhibited when metformin 
was combined with erlotinib. AICAR treatment lacked 
these effects, again indicating that the enhanced inhibition 
on cell signaling with metformin observed is not solely 
AMPK-dependent (Fig. 2C). We confirmed the same 
potentiation of inhibitory effects on AKT, S6 and 4EBP1 
signaling in another BBC cell line, BT-20, which also has 
a strong basal EGFR signal output (Fig. 2D). We used 
an RTK antibody array to simultaneously assess whether 
other signaling pathways are changed by combination 
treatment, and found the levels of phosphorylated RTKs 
such as HER2, HER3, IGF-IR, and InsR were generally 
weak in MDA-MB-468 cells, and no significant changes 
were found (Suppl. Fig. 1A).
Metformin and erlotinib combined to induce 
apoptosis, reduce clonogenicity, and inhibit 
mammosphere formation
Assessment of cell proliferation and apoptosis 
in MDA-MB-468 cells under different drug treatments 
showed that the combination of metformin and erlotinib 
induced cell death, while each single agent treatment 
only partially inhibited proliferation and was unable to 
induce apoptosis (Fig. 3A). Western blot analysis showed 
significant increased expression of cleaved-caspase 3 for 
cells under combination treatment as compared with single 
agent treatments (Suppl. Fig. 1B). We also performed a 
cytotoxic clonogenic assay in MDA-MB-468 cells and 
observed that the combination treatment of metformin 
and erlotinib significantly reduced, and almost eliminated, 
colony formation as compared with single agent treatments 
(Fig. 3B). We included rapamycin for comparison and 
observed that the metformin and erlotinib combination 
was superior to the rapamycin and erlotinib combination 
at a dosage that resulted in similar S6 inhibition. We also 
compared the effect of metformin and erlotinib versus 
their combinations with other inhibitors of relevant 
pathways revealed in our signaling experiment in MDA-
MB-468 cells. These combinations include combining 
metformin with MK2206 (an allosteric AKT inhibitor), 
metformin with GSK1120212 (an allosteric MEK1 and 
MEK2 inhibitor), and erlotinib with AZD8055 (an ATP-
competitive mTOR kinase inhibitor). We found that when 
these drugs were all used at their IC40 concentrations, 
the combination of metformin with erlotinib was superior 
to all other combinations tested as measured by growth 
inhibition over 6 days in MDA-MB-468 cells (Suppl. 
Fig. 2).
To investigate the effect of the drug combination 
on an enriched cancer stem cell population that forms 
mammospheres in non-attaching and serum-free culture 
conditions, we performed mammosphere formation 
assays in the presence of different drug treatments. 
We observed complete inhibition of mammosphere 
formation in MDA-MB-468 cells treated with both drugs 
while treatment with metformin or erlotinib as single 
agents only partially inhibited mammosphere formation 
(Fig. 3C). The ability of the combination to inhibit 
mammosphere outgrowth was confirmed in other BBC 
cell lines and suggested a more indiscriminant effect 
since the inhibition was seen in lines that showed only 
additive, or even antagonistic effects in our cell viability 
assays (Suppl. Fig. 3A-B).
To further confirm the ability of the drug combination 
of metformin and erlotinib to induce apoptosis, we tested 
the eight cell lines that were synergistically inhibited by the 
drug combination in the cell viability assay (Table 1) using 
flow cytometry to assay for cell death. Six of the eight cell 
lines (MDA-MB-468, HCC-1937, L56BrC1, HCC70, 
MCF7 and BT-20) exhibited significant cell death, ranging 
from 13.6 % to 55.4%, under the combination treatment as 
compared with no increase in cell death with single drug 
treatments (Fig. 3D).
To further explore whether AMPK is involved in 
the synergistic effect from the combination treatment, 
we knocked down AMPK-a1 using lentiviral shRNA. 
Although AMPK-a1 knockdown generally made the 
MDA-MB-468 cells more resistant to metformin 
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(Suppl. Fig. 4), the combination of metformin and 
erlotinib still produced synergistic cell death (Fig. 3E). We 
also tried a more potent biguanide phenformin. 0.1 mM 
of phenformin induced strong AMPK phosphorylation 
comparable to 0.8 mM, but the synergistic effect from 
combination with erlotinib was only evident at higher 
doses as 0.4 or 0.8 mM (Fig. 3F). These data along with 
the data from AICAR (Fig. 2C) suggest that AMPK 
activation is not solely responsible for the synergistic 
effect for the combination of metformin or phenformin 
with erlotinib.
Recent studies show that carbon sources affect the 
sensitivity to metformin [27, 38, 39]. We tested the effect 
of glucose on the synergism of metformin and erlotinib 
Figure 3: Combined treatment with metformin and erlotinib induces cell death in various breast cancer cell lines and 
reduces clonogenicity as well as mammospheres formation in MDA-MB-468 cells. (A) Proliferation assay of MDA-MB-468 
cells treated with metformin (1 mM), erlotinib (4 µM), and their combination over 6 days. (B) Clonogenic assay on MDA-MB-468 cells 
treated with metformin (0.5 mM), erlotinib (4 µM), rapamycin (10 nM) and their combination over 2 weeks. (C) Mammosphere formation 
assay on MDA-MB-468 cells treated with metformin (2 mM), erlotinib (4 µM) and their combination for 6 days. (D) 8 cell lines were 
treated with metformin (0.5, 1 or 2 mM) and erlotinib (4 µM) and their combination for 3 days and assayed for cell death using the FITC 
Annexin V Apoptosis Detection Kit I for flow cytometry analysis. This data is representative of the results from 3 separate experiments 
for each cell line. (E), MDA-MB-468 cells were transduced with scramble PLKO.1 and AMPK-a1 shRNA lentiviruses and subjected to 
puromycin selection. Cells were further treated with vehicle control, 1 mM metformin (M1), 4 uM erlotinib (E4), or combination (M1+E4). 
Apoptotic cells were detected with Annexin V-FITC and PI staining. Apoptotic cell percentage from vehicle control was deducted from 
treatment groups. Mean +− S.D. of Annexin-V positive cells were shown (n=4). (F), MDA-MB-468 cells were treated with 4uM erlotinib 
and different doses of phenformin. Mean +− S.D. of Annexin-V positive cells were shown (n=3). To detect the level of p-AMPK, cells were 
treated with phenformin for 24 hr. (G), MDA-MB-468 cells were treated with vehicle control, 1 mM metformin (M1), 4 uM erlotinib (E4), 
or combination (M1+E4) in growth medium (containing 10% FBS, 4 mM glutamine) supplemented with 25 mM, 5 mM or 0 mM glucose. 
Mean +− S.D. of Annexin-V positive cells were shown (n=3).
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combination. 25 mM is the high glucose concentration 
in regular DMEM medium for MDA-MB-468, and 5 
mM of glucose is close to physiological level found in 
serum. We found that the synergistic effect at 5 mM was 
comparable to 25 mM (Fig. 3G), but diminished in culture 
medium without glucose, although cells were generally 
more sensitive to either drug alone or combination under 
extreme low glucose condition.
Consistent with endogenous BIM expression 
in cancer cells being a determinant of apoptotic 
responsiveness to kinase inhibitors, including EGFR 
inhibitors [40], we observed that the two lines that 
did not show evidence of apoptosis upon combined 
drug traetment (MDA-MB-436 and MDA-MB-435S) 
expressed the lowest amount of endogenous BIM protein 
(Suppl. Fig. 5). All together, these results show that 
metformin combined with erlotinib synergize to inhibit 
a subset of breast cancer cell lines grown and assayed in 
multiple in vitro contexts.
PTEN is one determinant of sensitivity to 
combined treatment with metformin and 
erlotinib
To further investigate whether PTEN affects 
sensitivity towards the drug combination, we utilized 
isogenic cell line models. We first compared a PTEN-
null MCF10A line, derived by deletion of exon 2 of 
PTEN on both alleles, with its parental MCF10A line. 
In addition, we compared the MCF10A parental line 
with the PTEN-null line engineered to overexpress both 
dominant negative p53 (dnp53) and wild type EGFR 
(named “ΔPTEN-dnp53-EGFR”) [41], mimicking these 
common concurrent genetic alterations present in BBCs 
(Fig. 4A). We observed that the combination treatment 
induced cell death in the PTEN-null isogenic cells 
and MCF10A ΔPTEN-dnp53-EGFR cells while only 
inhibiting proliferation in the PTEN wild type MCF10A 
parental cells (Fig. 4B). Both PTEN-null cell lines 
Figure 4: PTEN-null isogenic MCF10A cells shows increased sensitivity towards combined treatment with metformin 
and erlotinib. (A) Immunoblots confirming genetic alterations in the MCF10A isogenic lines. (B) Proliferation assays of parental, 
PTEN-null and ΔPTEN-dnp53-EGFR MCF10A cells treated with metformin (4 mM), erlotinib (4 µM) and their combinaton over 6 days. 
6 replicates were used per treatment (* represents p < 0.03 and ** represents p < 0.0001). (C) Immunoblot analysis of EGFR, AKT and 
S6 signaling in parental and ΔPTEN-dnp53-EGFR MCF10A cells treated with metformin (4 mM), erlotinib (4 µM) and their combination 
for 1 hour.
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were also more sensitive towards metformin treatment 
as compared with the parental line. We then looked for 
differential inhibition of signaling pathways between the 
cell lines. As expected, phosphorylation of EGFR and 
AKT were both significantly upregulated in the ΔPTEN-
dnp53-EGFR line and substantially inhibited by treatment 
with erlotinib (Fig. 4C). Interestingly, the synergy of the 
combined treatment could be clearly observed through 
enhanced inhibition of S6 in ΔPTEN-dnp53-EGFR cells 
as compared with single agent treatments, and this effect 
was less pronounced in the MCF10A parental line. To 
assess the converse isogenic experiment, we introduced 
PTEN into the PTEN-null cell lines MDA-MB-468 and 
HCC-1937 which, in both cases, resulted in reduced AKT 
phosphorylation and a decrease in synergy (increased 
CI) to the drug combination (Suppl. Fig. 6A-D). These 
results indicate that loss of PTEN sensitizes breast cancer 
cells to combined metformin and erlotinib treatment and 
supports the assertion that PTEN status is one determinant 
of combined drug treatment sensitivity.
To test whether other PI3K pathway alterations 
can induce the synergism, and whether such synergism is 
applicable to other cancer types, we treated glioma cancer 
cell line H4, lung cancer cell line NCI-H1975, and ovarian 
cancer cell line CAOV-3 with metformin or phenformin 
(when cell line is resistant to metformin), and erlotinib. 
Based on cBio cancer genomics portal [37], H4 cell line 
has PTEN homozygous deletion and EGFR amplification; 
NCI-H1975 and CAOV-3 both have a PIK3CA mutation 
and an EGFR mutation. All three cell lines showed 
synergistic and/or additive cell death under combination 
treatment (Suppl. Fig. 7), which further confirms that 
PTEN status and/or PI3K pathway alteration may be one 
of the determinants for the synergism between biguanide 
and erlotinib combination, and such synergism can be 
applied to cancer types other than breast cancer.
Combination treatment of metformin and 
erlotinib induces tumor regression in a mouse 
orthotopic transplant model
Next, we assessed the efficacy of the combination 
treatment in vivo using an orthotopic transplant MDA-
MB-468 cell xenograft model. The combination treatment 
resulted in tumor regression (28% decrease by volume) 
while the individual treatments each only marginally 
slowed tumor growth (68% increase by volume in the 
cohort treated by metformin and 35% increase by volume 
in the cohort treated by erlotinib) over a course of 21 days 
(Fig. 5A). Tumor weights at the end of the experiment 
confirmed a significant reduction of tumor burden 
(69% reduction compared with control) with the drug 
combination as compared with single agent treatments 
(Fig. 5B). We did not observe any toxicity in any of the 
cohorts. Measured plasma trough levels of both drugs 
taken at the time the tumors were harvested (24 hours after 
their last treatment) were low [metformin (0.17 µM) and 
erlotinib (0.12 µM)]. We asked if altered circulating insulin 
played a role in the observed tumor regression but found 
that trough plasma insulin levels were not significantly 
different between the cohorts (Suppl. Fig. 8). Combined 
treatment using a 5-fold lower dose of metformin 
(50 mg/kg/day) also inhibited xenografted PTEN null 
HCC-70 BBC cells (Suppl. Fig. 9). To thoroughly 
understand the drug concentration in plasma, we treated 
mice with metformin 50 mg/kg and 50 mg/kg erlotinib and 
conducted a pharmacokinetics study (Suppl. Fig. 10). For 
erlotinib the Cmax was 7283 ± 1344 ng/mL (18.5 uM) and 
the trough level was < 0.25 ng/ml with a terminal half-life of 
1.5 hours. For metformin, the Cmax was 1828 ± 259 ng/mL 
(14.2 uM), the trough level was 2.9 ± 0.4 ng/ml and the 
terminal half-life was 3 hours. There was no accumulation 
of either drug consistent with pulse daily dosing 
(see supplemental PK data for full modeling details).
Metformin and erlotinib combined to inhibit cell 
signaling and induce apoptosis in vivo
Tumors were harvested 24 hours after their last 
treatment and assessed by immunohistochemcial staining. 
The apoptosis marker, cleaved caspase 3, revealed 
significantly more apoptosis (13.6%) in the combined 
treated tumors (Fig. 5C). On the other hand, Ki-67 and 
phospho-Histone H3 staining showed that proliferation 
was not preferentially affected (data not shown). As 
expected, control tumors showed very high activation 
of EGFR as shown by intense membranous staining of 
p-EGFR at the Tyr1143 residue. Erlotinib alone, and 
metformin alone (to a lesser extent), reduced EGFR 
phosphorylation, while the combined treatment completely 
inhibited EGFR phosphorylation (Fig. 5D; Suppl. Fig. 11). 
Control tumors showed almost no AMPK phosphorylation 
while metformin, as shown in both single and combined 
treatments, significantly activated AMPK. We found highly 
phosphorylated AKT in the control tumors as shown by 
intense membranous staining (Fig. 5D). Erlotinib alone 
partially reduced AKT phosphorylation and surprisingly, 
metformin alone also significantly inhibited AKT 
phosphorylation in these tumors. Importantly, we observed 
almost complete inhibition of AKT phosphorylation in 
tumors treated with the combined therapy. These signaling 
changes were all consistent with what was observed in vitro. 
These results show that the combination of metformin and 
erlotinib synergize to trigger significant apoptosis that 
neither drug alone can achieve, while collaborating to inhibit 
both upstream and downstream PI3K pathway signaling.
DISCUSSION
To date, no effective targeted therapies are available 
for BBCs. The catalog of documented genetic alterations 
found in BBC tumors, with many occurring concurrently, 
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suggests that single agent targeted therapies are unlikely 
to be effective in most patients. We show, for the first 
time, that metformin can synergize with a targeted drug, 
erlotinib, to induce tumor regression in an orthotopic 
transplanted BBC model while demonstrating that loss of 
PTEN is one potential marker of sensitivity.
We demonstrated that metformin and erlotinib can 
have synergistic or additive effects in a significant subgroup 
of BBC cell lines. It was encouraging to find that in most 
of the “synergistic” cases, the synergy was caused, at least 
in significant part, by induction of apoptosis. Our screen 
across a panel of 17 breast cancer lines with known PTEN 
mutation status and differential effects seen in the isogenic 
cell lines with and without PTEN expression are evidence 
that PTEN is a candidate biomarker of sensitivity towards 
the drug combination. PTEN expression was present 
Figure 5: Combined treatment of metformin and erlotinib induces tumor regression, inhibits drug targets in vivo and 
induces apoptosis in MDA-MB-468 xenograft model. (A) Tumors formed by MDA-MB-468 cells in mice were treated with 
metformin (250 mg/kg/day), erlotinib (50 mg/kg/day) and their combination via oral gavage 6 days a week for 21 days. Tumor growths 
were monitored over 21 days by caliper measurements every 3 days. A minimum of 6 tumors were used per arm. (B) Tumors were excised 
24 hours after last drug treatments and final tumor weights were obtained. (C) Apoptosis in tumors excised 24 hours after last drug 
treatments were assessed by immunohistochemistry (IHC) using cleaved caspase 3 antibody and results were quantitated (6 or 7 samples 
per treatment group). 3 views were counted per sample. Length of scale bar equals 50 µm. (D) Signaling status of EGFR, AKT and AMPK 
in tumors excised 24 hours after last drug treatments was assessed by IHC. Length of scale bar equals 50 µm.
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among all the cell lines in the antagonistic group with the 
exception of HCC-38. Possible explanations for the lack of 
synergy in PTEN-null HCC-38 cells include 1) the fact that 
it harbors a fusion gene comprised partly of the SLC22A1 
gene (which codes for OCT1) fused with CUTA (from 
the Sanger mutation database), 2) it has the lowest level 
of phosphorylated EGFR among the 17 cell lines (data 
not shown) and, 3) existence of other unknown genetic 
alterations in the relevant signaling pathways. Further 
investigation of the mechanism of resistance towards the 
combination treatment in HCC-38 cells is warranted.
Since loss of PTEN increases the synergy of the 
drug combination and gain of PTEN decreases the 
synergy, the synergy is likely in part due to activation of 
the PI3K pathway and thus dependent on a subset of its 
signal outputs. Inhibition of one PI3K output, mTOR, 
has previously shown to synergize with EGFR inhibition 
[42] so one obvious explanation for the observed synergy 
is metformin’s ability to directly and indirectly inhibit 
mTOR [30, 31]. Although we also confirmed the ability 
of metformin to inhibit S6 and 4EBP1 phosphorylation 
independently of AMPK activation, the observation that 
erlotinib in combination with metformin outperformed 
erlotinib in combination with either rapamycin or 
AZD8055 (TORC kinase inhibitor) suggests that 
additional factors are contributing to our observed synergy. 
One observed difference between combining erlotinib with 
metformin as opposed to specific mTOR inhibition was a 
significant additional decrease in EGFR phosphorylation. 
This potentiation of the inhibitory effect of erlotinib on 
EGFR by metformin was also not observed when erlotinib 
was combined AICAR so it is unlikely due to activation of 
AMPK. These observations are novel and require further 
study. We also showed that metformin treatment combined 
with either an AKT or MEK inhibitor in place of erlotinib 
generated an inferior inhibitory effect. These results 
may be explained by the fact that there was no observed 
stimulatory feedback when erlotinib was combined with 
metformin. In fact, the combination of metformin and 
erlotinib resulted in potentiation of decreased AKT and 
EGFR phosphorylation instead of previously described 
feedback resulting in increased phosphorylation of 
AKT with rapamycin treatment or increase EGFR 
phosphorylation with AKT inhibitor treatment [43, 44]. 
No other signaling pathway alterations were detected in 
RTK antibody array.
Data from TCGA confirms that activation of the 
PI3K-AKT pathway is high in the majority of BBCs as 
compared with other subtypes of breast cancer [1]. Using 
the cBIO Cancer Genomic Portal, we confirmed the well-
established enrichment of relatively increased EGFR 
mRNA in BBC [RNAseq z-score > 1 in 14/81 (28%) of 
BBC versus 6/324 (2%) of luminal cases. p < 0.0001 by 
Fisher Exact Probability Test] [37]. More importantly, 21 
out of 23 of the BBC with “high” EGFR mRNA levels 
have a concurrent alteration in the PI3K pathway (PTEN, 
INPP4B, AKT1/2/3, or PIK3CA; data not shown). Instead 
of PTEN mutation, BT-20 (a basal line) and MCF7 (a 
luminal line) cells in the “synergistic group” harbor 
PIK3CA mutations and increased phosphorylation of 
EGFR. Thus it is reasonable to suggest that erlotinib and 
metformin could have therapeutic potential in any breast 
cancer driven by activated EGFR and PI3K pathways. 
Importantly, we observed in our short panel of breast 
cancer cell lines that although expression of EGFR was 
much lower in the luminal cell lines, the phosphorylation 
status was very comparable to that of the basal-like lines. 
This observation is consistent with the TCGA proteomic 
breast cancer data in which, despite the difference in 
total EGFR mRNA levels between basal and luminal 
cases, levels of phosphorylated EGFR between basal and 
luminal subtypes were similar (26% of basal and 24% 
of luminal case with p-EGFR protein z-scores > 1) [37]. 
One could further speculate that the synergy between 
EGFR inhibition and metformin may occur in other tumor 
types enriched for concurrent EGFR and PI3K pathway 
activation, including squamous cell cancers, colorectal 
cancer, glioblastoma with EGFR vIII amplification, and 
lung cancer with EGFR exon 18 through 21 mutations. 
In fact, we detected synergistic cell death from three 
other cancer lines H4, CAOV-3 and NCI-H1975, which 
harbor either PTEN or PI3KCA mutation and EGFR 
amplification or mutation. There is a recent study showing 
that metformin synergizes with another EGFR inhibitor 
gefitinib in lung cancer cell lines [45].
We also investigated if LKB1, upstream of AMPK, 
played any role in the observed synergy. Reducing the 
LKB1 protein level via shRNA in MDA-MB-468 cells 
showed no effect on synergy towards the drug combination 
(data not shown) suggesting that either metformin requires 
only a small amount of basal LKB1 to activate AMPK or 
metformin’s antineoplastic effects are largely independent 
of LKB1. Our cell signaling data suggest that the synergy 
is independent of LKB1 and is further supported by our 
observation that the drug combination has an additive 
effect on SUM-149 cells, which lacks LKB1 expression. 
Our data are consistent with the previous observation that 
metformin and phenformin were able to delay outgrowth 
of PTEN deficient and LKB1 hypomorphoic xenografts in 
the absence of significant changes in insulin levels [32].
It has been shown that metformin can inhibit 
tumor initiating cells and prevent relapses in vivo when 
combined with chemotherapy [21]. In our study, we 
found that metformin or erlotinib alone can inhibit 
mammosphere formation in multiple BBC cell lines. This 
confirms previous findings that EGFR inhibition leads to 
reduced mammosphere formation in breast cancer cells 
when co-cultured with mesenchymal stem cells [46]. We 
showed that combining the two drugs was significantly 
more potent compared with either alone and completely 
prevented mammosphere formation in multiple BBC 
cell lines. The reason for this result warrants further 
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investigation and supports the hypothesis that the drug 
combination may help prevent relapses in BBC patients.
It is controversial whether the effects of metformin 
at high concentrations have translational value. 
Metformin was used at doses of 0.5 to 4 mM in many 
of our in vitro studies. Although much higher than the 
plasma level in patients (about 10 µM) [47], these doses 
are lower than most of the published in vitro data, with the 
notable exception of metformin’s ability to inhibit tumor 
initiating cells [21]. AMPK activation was demonstrated 
in muscle biopsies from patients given typical diabetic 
doses of metformin which agrees with our data showing 
that much lower levels (micromolar) of metformin are 
needed in vivo to obtain the same cell signaling changes 
which require millimolar concentrations in vitro [48]. 
Increased p-AMPK (Thr 172) immunohistochemical 
staining was also seen in the HCC-70 xenografted tumors 
treated with 50 mg/kg/day of metformin (data not shown). 
Therefore, the higher concentrations of metformin needed 
for in vitro experiments are likely, at least in part, due 
to artifacts of non-physiologic tissue culture conditions 
[27]. Recently there have been two reports showing that 
intermediate concentrations of metformin (300–500 
µM) can reprogram cancer cell metabolism [49, 50]. 
Furthermore, we had the observation that glucose levels 
can affect the inhibitory effect of metformin on breast 
cancer cells in vitro as others have observed in other 
settings [Fig. 3G; [27, 38, 39]]. Under physiological 
level of glucose (5 mM), we still observed similar level 
of synergism. Although cells in low glucose medium are 
more sensitive to treatment, the synergism diminishes 
compared to normal glucose level.
There is also evidence that metformin can accumulate 
within tissues leading to higher concentrations than plasma 
levels [51]. Our immunohistochemistry results demonstrate 
that the drug-induced signaling alterations of EGFR, AKT, 
and AMPK were maintained 24 hours after administering 
the last dose of metformin and erlotinib, corresponding 
to the concurrently measured low micromolar plasma 
levels of each drug, which is consistent with their reported 
half-lives in mice of about 3 hours. We did not observe 
differences in plasma insulin levels between the mouse 
cohorts, suggesting that the observed signaling effects were 
due to a direct interaction of the drugs with tumor cells. 
However, the potential effects of altered growth factor 
levels by metformin cannot be completely discounted by 
our data, especially given the rapid kinetics of growth 
factor levels (e.g. the half-life of insulin in mice is 10 min) 
[52]. Despite the limitations of our studies, our aggregate 
observations, and the ability of the drug combination to 
induce apoptosis with resulting tumor regression in vivo, 
demonstrates translational potential.
Our study provides evidence that combination 
therapy with metformin and erlotinib could have 
therapeutic efficacy in cancers driven by EGFR and 
PI3K signaling, including a subset of BBC patients, and 
provides a rationale for clinical study. Both metformin 
and erlotinib are well-tolerated orally administered  FDA-
approved drugs that can be easily translated into clinical 
trials and could serve as a platform for the addition of 
other targeted drugs and chemotherapy.
Statement of significance
BBCs make up the large majority of the triple 
negative clinical subtype of breast cancers (TNBCs) 
and are aggressive tumors deficient of effective targeted 
therapies. Our in vitro and in vivo data show that 
combining metformin with erlotinib may be considered in 
strategies to treat TNBCs, with loss of PTEN expression 
as one candidate biomarker of sensitivity.
METHODS
Human breast cell lines
MDA-MB-468, MDA-MB-157, MCF7, MDA-
MB-435S, BT-20, MDA-MB-436, MX-1, L56Br-C1, 
MDA-MB-231, and CAOV-3cells were obtained from 
American Type Culture Collection (ATCC) and cultured 
in DMEM media and 10% fetal bovine serum (FBS). 
HCC-1143, HCC-1806, HCC-1937, HCC-70, HCC-38, 
HCC-1187, BT-549 cells were obtained from ATCC and 
cultured in RPMI-1640 media and 10% FBS. Glioma 
cell line H4 was kindly gave to us by Dr. Richard Baer 
(Columbia University) and cultured in DMEM media 
and 10% FBS. Lung cancer cell line NCI-H1975 was 
kindly gave to us by Dr. Balazs Halmos (Columbia 
University) and cultured in RPMI-1640 media and 10% 
FBS. SUM-149 cells were cultured in HAM’s F12 media 
and 10% FBS supplemented with insulin (10 µg/ml) 
and hydrocortisone (500 ng/ml). HMEC-hTERT cells 
were kindly given to us by Dr. Robert Weinberg and 
cultured in DMEM/F12 media supplemented with EGF 
(10 ng/ml), hydrocortisone (250 ng/ml) and insulin 
(10 µg/ml). MCF10A parental cells and MCF10A PTEN-
null cells were kindly given to us by Dr. Kurtis Bachman 
[53]. Derivatives were made by infecting MCF10A 
PTEN-null cells with retroviral vector pBABE-DDp53-
hyg (Addgene plasmid 9058) and pBABE-EGFR-
puro (Addgene plasmid 11011) as described in [41]. 
All MCF10A lines were cultured in DMEM/F12 media 
and 5% horse serum supplemented with EGF (20 ng/
ml), hydrocortisone (500 ng/ml), insulin (10 µg/ml) and 
cholera toxin (100 ng/ml). All cells were cultured with 
1% penicillin/streptomycin at 37oC with 5% CO
2.
Reagents
Metformin and phenformin were obtained from 
Sigma-Aldrich. Erlotinib and rapamycin were obtained 
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from LC Laboratories. AICAR was obtained from Cell 
Signaling. BIBW2992 and AZD8055 were obtained from 
Selleck Chemicals. MK2206 and GSK1120212 were 
obtained from the Stand Up To Cancer drug inventory.
Antibodies
Antibodies obtained from Cell Signaling 
Technologies: Anti- phospho-AMPK(T172), pan 
AMPKα, phospho-ACC(S79), phospho-EGFR(Tyr1173), 
phospho-S6(S235/236), phospho- S6(S240/244), phospho-
4EBP1(T70), 4EBP1(53H11), phospho-Erk1/2 (Thr202/
Tyr204), Erk1/2, phospho-AKT(S473), AKT, cleaved 
caspase 3, LKB1(27D10), PTEN(138G6), BIM (C34C5) 
and phospho-Histone H3. Antibodies obtained from Santa 
Cruz: EGFR, S6. Anti-phospho-EGFR(Tyr1173) and 
anti-AMPK-a1 antibodies were obtained from Millipore. 
Anti- SLC22A1 (OCT1) and Ki-67 antibodies were 
obtained from Abcam. Anti-SLC22A2 (OCT2) antibody 
was obtained from Sigma-Aldrich. Anti-p53 antibody was 
obtained from Calbiochem.
Analysis of cytotoxic interactions between 
metformin and erlotinib
Each cell line seeded at 10,000 cells/well in 48-well 
plates was treated with the following drug treatments: 
metformin (0.5, 1, 2, 4 mM), erlotinib (2, 4 µM) and 
combination of metformin and erlotinib at all these doses. 
6 replicates were used for each treatment. Cell viability 
was assessed by crystal violet assay after 6 days of drug 
treatments. The combination index (CI) reflecting additive 
(0.8–1.2), synergistic (< 0.8) and antagonistic (>1.2), 
was obtained by using the software Compusyn (version 
3.01). We have modified the stringency of the analysis by 
defining “additive” as cell lines having CI between 0.8 
and 1.2 instead of exactly at 1. This experiment was also 
carried out in PTEN-null MDA-MB-468 cells and HCC-
1937 cells retrovirally transfected with the plasmids 1066 
pBabe puroL PTEN (plasmid #10785 from Addgene) and 
pBabe -puro (plasmid #1764 from Addgene).
Western blot analysis
Cells were lysed with 2X Laemmli buffer. 25 µg 
of total proteins were separated by electrophoresis 
and transferred to polyvinylidene fluoride membranes. 
Membranes were incubated with primary antibodies 
followed by secondary antibodies and then developed with 
an enhanced chemiluminescence detection kit according to 
manufacturer’s instructions.
Proliferation assay
6-well proliferation assay: 400,000 cells/well were 
seeded, treated every 2 days and grown for 6 days. Cell 
number was obtained every 2 days. 48-well proliferation 
assay: 10,000 cells/well were seeded, treated every 3 days 
and grown for 6 days. Cells were stained with 0.05% 
crystal violet solution at the end of the experiment and 
absorbance was measured at 590 nm.
Cytotoxic clonogenic assay
Cells were seeded in 6-well plate at a sparse 
density of 800 cells/well and treated with various drugs 
(metformin = 0.5 mM, erlotinib = 4 µM, rapamycin = 
10 nM) and their combinations for 3 days. Colonies were 
counted after culturing for 2 weeks.
RTK signaling antibody array
MDA-MB-468 cells were seeded in 6-well plate and 
treated with vehicle control (Ctrl), metformin (1 mM), 
erlotininb (4 µM) and their combination for 24 hours. The 
samples were processed according manufacture’s protocol 
(Cell Signaling).
Mammosphere formation assay
Cells were seeded at 20,000 cells/well in 
ultralow attachment 6-well plate in DMEM/F12 media 
supplemented with B27, EGF (20 ng/ml), insulin 
(10 µg/ml) and hydrocortisone (70 ng/ml) and allowed to 
grow for 6 days. The majority of cells could not survive 
under non-attachment conditions and only cells capable 
of forming mammospheres proliferated. The number of 
mammospheres was counted 6 days after the start of the 
drug treatments.
Flow cytometry
Cells were seeded at 60,000 cells/well and treated 
with metformin (0.5, 1 or 2 mM) or erlotinib (4 µM) and 
their combination. Cells were then trypsinized and stained 
with both FITC Annexin V antibody and propidium iodide 
(PI) to assay for cell death after 3 days using the FITC 
Annexin V Apoptosis Detection Kit I (Becton Dickenson). 
Procedures were carried out according to manufacturer’s 
instructions. Fluorescence-activated cell sorting (FACS) 
analysis was performed on a BD FACSCalibur flow 
cytometer (Becton Dickenson) and the results were 
analyzed using the software FlowJo (Tree Star Inc) .
In vivo drug treatment study
All animal experiments were conducted according 
to protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) at Columbia University 
Medical Center. 1 million MDA-MB-468 cells mixed 
with Matrigel were injected into the mammary fat pad 
of each mouse and allowed to grow into tumors with size 
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of approximately 125 mm3. The mice were randomized 
into 4 groups (6 to 7 animals per group) and treated with 
metformin alone (250 mg/kg/day), erlotinib alone (50 mg/
kg/day), metformin and erlotinib, or DMSO through 
daily oral gavage (6 days per week). Tumor size was 
measured every 3 days up to 21 days. 24 hours after the 
final drug treatments, tumors were excised and weighted 
by a digital scale. Trough plasma levels of metformin 
and erlotinib were assessed by ultra performance 
liquid chromatography and tandem mass spectrometry 
using a Zorbax Eclipse XDB C18 column, an Agilent 
1290 UPLC and an Agilent 6410 triple quadrupole mass 
spectrometer. Cmax levels of metformin and erlotinib 
were simulated based on individualized compartmental 
pharmacokinetic parameters for each drug derived 
from earlier reports [51, 54] using a model developed 
previously [55] and the MW-Pharm pharmacokinetic 
software (Mediware). Plasma insulin level was measured 
by ALPCO Insulin Assay according to manufacturer’s 
instructions (ALPCO Diagnostics). Excised tumors were 
fixed in 10% formalin and stained with various antibodies 
for immunohistochemical analysis.
Pharmacokinetics study
A limited sampling method and modeling was used. 
Groups of 3 mice each were treated with metformin (50 
mg/kg/day) and erlotinib (50 mg/kg/day) by oral gavage 
for 6 out of 7 days for 3 weeks total. Mice were sacrificed 
for plasma collection at the following time-points: 
Day 1 [1 hr, 2 hr, 4 hr, 8 hr and 24 hr (day 2 trough)], 
immediately prior to the day 6 dose [day 6 trough], one 
hour after the day 6 dose [day 6 peak], and 4 hours after 
the last treatment. See supplemental PK methods and 
results for full details.
Statistics
Student’s two-tailed t-test was used to analyze 
statistical differences between experimental groups.
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